Skip to main content
. Author manuscript; available in PMC: 2017 Aug 30.
Published in final edited form as: Cell Rep. 2016 Aug 18;16(9):2428–2441. doi: 10.1016/j.celrep.2016.07.058

Figure 6. GATA2, IL1B, and CXCL2 Expression in AML Patients.

Figure 6

(A) Heatmap depicts 19,798 genes, based on ranking of the correlation with GATA2 expression.

(B) Heatmap depicts GATA2, CXCL2, and IL1B mRNA correlations.

(C) Scatterplot depicts correlations among GATA2, CXCL2, and IL1B mRNA expression in M5-AML patients.

(D) Real-time RT-PCR analysis of CXCL2 and IL1B mRNA in Kasumi-1 cells treated with 10 ng/ml IL-1β or 100 ng/ml CXCL2 (n = 3, mean ± SE). Kasumi-1 cells were serum-starved overnight and treated with IL-1β or CXCL2 for 30 min (*p < 0.05).

(E) Kaplan-Meier plots compare overall survival of patients with high versus low GATA2, CXCL2, or IL1B mRNA.

(F) Kaplan-Meier plots depict overall survival of patients with high versus low GATA2/IL1B mRNA, GATA2/CXCL2 mRNA, and IL1B/CXCL2 mRNA. This analysis was based on the cohort of 163 patients with CN-AML from the GEO: GSE12417 dataset (Metzeler et al., 2008).

See also Figures S6 and S7.